Moreover, the anti-tumor activity seen with the combination was associated with a further increase in CD8+ T cells and unique T cell clones in the tumor, supporting the evaluation of this combination in phase 2 and 3 trials in mRCC and in other tumor types. This evidence concerns the gene CD8A and neoplasm.